BR9712085A - Inibidores de metaloprotease heterocìclicos - Google Patents

Inibidores de metaloprotease heterocìclicos

Info

Publication number
BR9712085A
BR9712085A BR9712085-5A BR9712085A BR9712085A BR 9712085 A BR9712085 A BR 9712085A BR 9712085 A BR9712085 A BR 9712085A BR 9712085 A BR9712085 A BR 9712085A
Authority
BR
Brazil
Prior art keywords
inhibitors
metalloprotease inhibitors
pharmaceutical compositions
metalloprotease
compounds
Prior art date
Application number
BR9712085-5A
Other languages
English (en)
Inventor
Stanislaw Pikul
Thomas Lee Cupps
Kelly Lynn Mcdow-Dunham
Biswanath De
Yetunde Olabisi Taiwo
Neil Gregory Almstead
Rimma Sandler Bradley
Michael George Natchus
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9712085A publication Critical patent/BR9712085A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES DE METALOPROTEASE HETEROCìCLICOS"<D>. A invenção proporciona compostos de fórmula (I), como descrito nas reivindicações, ou um isómero, diastereómero, ou enantiómero óptico destes, ou um sal farmaceuticamente aceitável ou amida, éster ou imida bio-hidrolisável dos mesmos, que são úteis como inibidores de metaloproteases. Também apresenta-se composições farmacêuticas e métodos de tratamento de doenças, distúrbios e condições caracterizadas por atividade de metaloprotease, fazendo uso desses compostos ou das composições farmacêuticas que os contêm.
BR9712085-5A 1996-08-28 1997-08-22 Inibidores de metaloprotease heterocìclicos BR9712085A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2484696P 1996-08-28 1996-08-28
PCT/US1997/014553 WO1998008823A1 (en) 1996-08-28 1997-08-22 Heterocyclic metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
BR9712085A true BR9712085A (pt) 2000-10-24

Family

ID=21822698

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712085-5A BR9712085A (pt) 1996-08-28 1997-08-22 Inibidores de metaloprotease heterocìclicos

Country Status (25)

Country Link
US (2) US6121258A (pt)
EP (1) EP0923561B1 (pt)
JP (1) JP3347331B2 (pt)
KR (1) KR20000035920A (pt)
CN (1) CN1228772A (pt)
AR (1) AR009457A1 (pt)
AT (1) ATE226573T1 (pt)
AU (1) AU734834B2 (pt)
BR (1) BR9712085A (pt)
CA (1) CA2263917A1 (pt)
CO (1) CO4920240A1 (pt)
CZ (1) CZ62699A3 (pt)
DE (1) DE69716615T2 (pt)
DK (1) DK0923561T3 (pt)
HU (1) HUP0000210A3 (pt)
ID (1) ID18416A (pt)
IL (1) IL128664A (pt)
NO (1) NO314934B1 (pt)
NZ (1) NZ334254A (pt)
PE (1) PE2599A1 (pt)
PL (1) PL331795A1 (pt)
SK (1) SK25799A3 (pt)
TR (1) TR199900382T2 (pt)
WO (1) WO1998008823A1 (pt)
ZA (1) ZA977696B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000035918A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,3-디헤테로시클릭 메탈로프로테아제 저해제
NZ503945A (en) 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
NZ505968A (en) 1998-02-04 2003-03-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
WO1999062880A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
AU6060299A (en) * 1998-09-30 2000-04-17 Procter & Gamble Company, The Method of treating hair loss using ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
JP2002531396A (ja) * 1998-12-02 2002-09-24 ファイザー・プロダクツ・インク p53ファミリーのタンパク質の配座安定性を回復するための方法及び組成物
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
NZ513830A (en) 1999-03-03 2001-09-28 Procter & Gamble Dihetero-substituted metalloprotease inhibitors
CZ20013176A3 (cs) 1999-03-03 2002-04-17 The Procter & Gamble Company Sloučenina vytvářející inhibitor metaloproteinasy, farmaceutický prostředek, způsob přípravy léčiva a léčivo
CN1188404C (zh) 2000-02-21 2005-02-09 藤泽药品工业株式会社 环化合物
MXPA03000043A (es) 2000-06-30 2003-10-15 Procter & Gamble Promocion de la salud en todo el cuerpo.
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
MXPA03011095A (es) * 2001-05-29 2005-04-28 Guilford Pharm Inc Metodo para tratar una lesion nerviosa causada por cirugia.
CA2464727A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
AU2004240629B2 (en) * 2003-05-16 2010-02-25 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
AU2004289287A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
JP4777738B2 (ja) * 2004-10-14 2011-09-21 株式会社 資生堂 Adam活性阻害物質によるしわの防止または改善
JP2007119444A (ja) * 2005-09-29 2007-05-17 Shiseido Co Ltd Adam阻害剤によるしわの防止または改善

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
DE4011172A1 (de) * 1990-04-06 1991-10-10 Degussa Verbindungen zur bekaempfung von pflanzenkrankheiten
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
IL98681A (en) * 1991-06-30 1997-06-10 Yeda Rehovot And Dev Company L Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives
DE4127842A1 (de) * 1991-08-22 1993-02-25 Rhone Poulenc Rorer Gmbh 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
ATE150452T1 (de) * 1992-04-07 1997-04-15 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
AU4267293A (en) * 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
ATE182581T1 (de) * 1994-06-22 1999-08-15 British Biotech Pharm Metalloproteinase-inhibitoren
EP0821671B1 (en) * 1995-04-20 2000-12-27 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
RU2164914C2 (ru) * 1995-11-13 2001-04-10 Хехст Акциенгезелльшафт ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ
DE69633947T2 (de) * 1995-12-08 2005-12-01 Agouron Pharmaceuticals, Inc., San Diego Zwischenprodukte zur Herstellung von Metallproteinasehemmern
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer

Also Published As

Publication number Publication date
CA2263917A1 (en) 1998-03-05
EP0923561B1 (en) 2002-10-23
DE69716615T2 (de) 2003-06-18
EP0923561A1 (en) 1999-06-23
JP2000516953A (ja) 2000-12-19
SK25799A3 (en) 1999-12-10
IL128664A0 (en) 2000-01-31
AU4153097A (en) 1998-03-19
CZ62699A3 (cs) 1999-07-14
NO990759D0 (no) 1999-02-18
US6399598B1 (en) 2002-06-04
HUP0000210A3 (en) 2001-07-30
NO990759L (no) 1999-04-27
JP3347331B2 (ja) 2002-11-20
PL331795A1 (en) 1999-08-02
TR199900382T2 (xx) 1999-05-21
PE2599A1 (es) 1999-03-03
ID18416A (id) 1998-04-09
AU734834B2 (en) 2001-06-21
DE69716615D1 (de) 2002-11-28
KR20000035920A (ko) 2000-06-26
US6121258A (en) 2000-09-19
ZA977696B (en) 1998-02-23
DK0923561T3 (da) 2003-02-24
WO1998008823A1 (en) 1998-03-05
NZ334254A (en) 2000-11-24
HUP0000210A2 (hu) 2001-04-28
IL128664A (en) 2003-07-06
CN1228772A (zh) 1999-09-15
CO4920240A1 (es) 2000-05-29
AR009457A1 (es) 2000-04-26
ATE226573T1 (de) 2002-11-15
NO314934B1 (no) 2003-06-16

Similar Documents

Publication Publication Date Title
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
BR9712086A (pt) Inibidores1,4-heterocìclicos de metaloproteinases
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
TR199900399T2 (xx) Matris metaloproteaz inhibit�rleri olarak fosfinik asit amidleri.
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA199900448A1 (ru) Производные 6-фенилпиридил-2-амина, полезные в качестве ингибиторов nos
PT966465E (pt) Inibidores do enzima imfdh
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
EA200100992A1 (ru) Ингибиторы фермента impdh
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE284690T1 (de) Antithrombotische diamine
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
EA199900632A1 (ru) 2-амино-6-(2-замещенные-4-фенокси)-замещенные-пиридины
BR9712792A (pt) Inibidores de metaloprotease bidentada.
EA200000165A1 (ru) Разветвленные алкоксизамещенные-2-аминопиридины в качестве ингибиторов nos
BG98827A (en) Pharmaceutical composition and method for its preparation
EE05085B1 (et) Pridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks henditeks
DE69819539D1 (de) Antithrombotische mittel
BR9811348A (pt) Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]